Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 16;223(12 Suppl 2):S194-S200.
doi: 10.1093/infdis/jiaa408.

Mechanisms of Colonization Resistance Against Clostridioides difficile

Colleen M Pike  1 , Casey M Theriot  1
Affiliations

Mechanisms of Colonization Resistance Against Clostridioides difficile

Colleen M Pike et al. J Infect Dis. .

Abstract

Clostridioides difficile is an urgent antimicrobial-resistant bacterium, causing mild to moderate and sometimes life-threatening disease. Commensal gut microbes are critical for providing colonization resistance against C difficile and can be leveraged as non-antibiotic alternative therapeutics for the prevention and treatment of C difficile infection.

Keywords: Clostridioides difficile; bacteria; bile acids; microbiota; short-chain fatty acids.

PubMed Disclaimer

References

    1. Smits WK, Lyras D, Lacy DB, Wilcox MH, Kuijper EJ. Clostridium difficile infection. Nat Rev Dis Primers 2016; 2:16020. - PMC - PubMed
    1. Guh AY, Mu Y, Winston LG, et al. ; Emerging Infections Program Clostridioides difficile Infection Working Group . Trends in U.S. Burden of Clostridioides difficile infection and outcomes. N Engl J Med 2020; 382:1320–30. - PMC - PubMed
    1. Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother 2014; 69:881–91. - PubMed
    1. Wolf J, Kalocsai K, Fortuny C, et al. Safety and efficacy of fidaxomicin and vancomycin in children and adolescents with Clostridioides (Clostridium) difficile infection: a phase 3, multicenter, randomized, single-blind clinical trial (SUNSHINE). Clin Infect Dis 2019. doi: 10.1093/cid/ciz1149 - DOI - PMC - PubMed
    1. Beinortas T, Burr NE, Wilcox MH, Subramanian V. Comparative efficacy of treatments for Clostridium difficile infection: a systematic review and network meta-analysis. Lancet Infect Dis 2018; 18:1035–44. - PubMed

Publication types

MeSH terms